ABION Announces Results of Respiratory Virus Treatment ABN 101 at 'PEPTalk'

Abion announced on the 22nd that it presented research results on the respiratory virus treatment ABN 101 at the global protein-related conference Peptalk 2024.

Peptalk is an international conference held annually since 2000, organized by the Cambridge HealthTech Institute. It took place in San Diego, USA, from the 16th to the 19th (local time).

ABN 101 is a dry powder respiratory virus treatment based on interferon beta, a protein with antiviral effects. It is manufactured with a median particle size of 2.5 micrometers, allowing delivery from the bronchi, where respiratory viruses infect, to the deep lungs.

Existing interferons have unstable properties, making powder formulation manufacturing impossible and production efficiency low. In contrast, ABN 101 increased productivity by about 80 times through proprietary technology, including modifying the amino acids of interferon beta and adding sugar chains.

The company stated, "In inhalation pharmacokinetics studies conducted through monkey efficacy evaluations, we confirmed virus suppression efficacy and maintenance results," adding, "Along with pharmacokinetics results, we also presented pharmacodynamics results showing increased gene expression related to antiviral activity."

They continued, "This means that the ABN 101 powder treatment can be developed as an effective antiviral agent," emphasizing, "We will accelerate clinical development to treat various respiratory viruses, including the reemerging COVID-19, influenza, and respiratory syncytial virus (RSV)."

Abion is currently conducting clinical trials for solid tumor treatments such as ABN 501, focusing on the non-small cell lung cancer c-MET (hepatocyte growth factor receptor) targeted anticancer drug ABN 401, and the respiratory virus treatment ABN 101.

This content was produced with the assistance of AI translation services.